4 transcripts
ARQT
Earnings call transcript
NASDAQ
2024 Q2
14 Aug 24
and also down sequentially from Q1 of this year due to lower spend in our early-stage programs.
You'll recall that we had some onetime spend in Q1
ARQT
Earnings call transcript
NASDAQ
2024 Q1
14 May 24
of topical roughly in the last, but flat as Q4 2023 due to slightly elevated onetime costs for Arcutis 234 as we continue to advance it to IND.
Recall
ARQT
Earnings call transcript
NASDAQ
2023 Q4
27 Feb 24
on topical roflumilast programs. And recall that our R&D expense includes research, operations and medical affairs spend.On Slide 22, looking at full
ARQT
Earnings call transcript
NASDAQ
2023 Q2
8 Aug 23
in psoriasis. And one additional update on the early pipeline. Recall that we started a Phase Ib study with our unique topical JAK for alopecia areata
- Prev
- 1
- Next